stockrow
Friday 6 November 2026
Export RLYB’s income statement to Excel — free account
Rallybio Corporation
RLYB Healthcare Biotechnology
Rallybio Corporation’s revenue for fiscal 2025 (year ended December 2025) was $858,000.00, up 34.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- −116.6%
- Free cash flow
- +65.3%
Quarter to September 2026, against a year earlier
15.74
0.16
−1.01%
Follow RLYB
Alert me
Rallybio Corporation (RLYB) P/E ratio
As of 5 November 2026, Rallybio Corporation (RLYB) trades at a P/E ratio of 3.3×. Over the past ten years it has ranged from 0.0× (June 2026) to 3.7× (September 2026); the current reading is higher than 98% of that period. That is below the Biotechnology industry median of 10.3× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.7×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GNLX Genelux Corporation compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| EQ Equillium, Inc. compare | n/m |
| CLLS Cellectis S.A. compare | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| RLYB Rallybio Corporation | 3.3× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)